This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide or pharmaceutical.
Beyond Semaglutide: Why the Next Generation Matters
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reshaped obesity pharmacotherapy. Semaglutide produces roughly 15-17% body weight loss in the STEP trials, while tirzepatide's dual GLP-1/GIP action pushed that ceiling to 20-22% in SURMOUNT-1. For years, those numbers looked like a ceiling. They are not.
Three molecules are now in advanced clinical development or early commercial launch with the potential to extend efficacy further, improve cardiovascular outcomes independently, and in one case eliminate the injection barrier altogether. Survodutide (Boehringer Ingelheim), mazdutide (Innovent Biologics / Eli Lilly), and amycretin (Novo Nordisk) each take a distinct mechanistic angle. Understanding the differences matters if you follow the obesity pharmacology space in 2026.
Survodutide: Dual GLP-1 / Glucagon Agonism
Survodutide (previously BI 456906) is a once-weekly injectable co-agonist of the GLP-1 receptor and the glucagon receptor (GCGR). The GLP-1 component suppresses appetite and slows gastric emptying via well-understood mechanisms. The added glucagon receptor agonism is the key differentiator: glucagon directly increases energy expenditure in brown adipose tissue, stimulates hepatic fatty acid oxidation, and reduces hepatic fat accumulation - effects that a pure GLP-1 agonist does not produce as strongly.
This mechanism makes survodutide particularly interesting for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), where hepatic fat clearance is as important as systemic weight loss. The tradeoff is that glucagon receptor agonism can raise blood glucose in isolation, so the GLP-1 component is essential to offset that hyperglycemic signal - hence the need for precise receptor balance in the molecule's design.
SYNCHRONIZE Trial Data
The Phase 2 SYNCHRONIZE trial evaluated survodutide across four dose levels (0.6 mg, 2.4 mg, 4.8 mg, and 6.0 mg weekly) against placebo in adults with overweight or obesity. At 46 weeks, the 6.0 mg cohort achieved approximately 18.7% mean body weight loss versus 1.0% for placebo - a 17.7 percentage point separation that positioned survodutide favorably against semaglutide's Phase 3 numbers at that stage of development.
Discontinuation rates due to adverse events were higher than in semaglutide trials, primarily driven by nausea, vomiting, and diarrhea - consistent with the glucagon component adding GI burden on top of the GLP-1 effects. Boehringer has since moved survodutide into Phase 3 SYNCHRONIZE-CVOT and a dedicated MASH program, with top-line results expected in 2026-2027.
In the MASH program (SYNCHRONIZE-NASH), survodutide showed histological improvement in liver fibrosis at 48 weeks, with a meaningful proportion of participants achieving MASH resolution without worsening fibrosis - a finding that semaglutide's NASH data did not replicate as strongly, likely due to the glucagon-mediated hepatic fat clearance.
Mazdutide: GLP-1 / Glucagon Agonism With a China-First Approval
Mazdutide (IBI362) is a once-weekly GLP-1/glucagon receptor co-agonist developed by Innovent Biologics with Eli Lilly involvement. Its mechanism parallels survodutide - dual receptor engagement targeting both appetite suppression and hepatic/adipose energy metabolism - but it has reached the market first, having received regulatory approval in China for obesity in 2024, making it the first dual GLP-1/glucagon agonist commercially available anywhere in the world.
GLORY Trial Data
The GLORY-1 and GLORY-2 trials evaluated mazdutide in Chinese adults with obesity or overweight and weight-related comorbidities. In GLORY-1 (3 mg and 4.5 mg weekly doses over 24 weeks in type 2 diabetes), mazdutide produced mean HbA1c reductions of approximately 1.6-2.2% alongside 5-8% body weight reduction. GLORY-2 in a non-diabetic obesity population showed stronger weight loss signal, with the 4.5 mg dose achieving approximately 12-14% body weight reduction at 24 weeks - a shorter duration than the SYNCHRONIZE data, making direct comparison imprecise.
Longer-term data from GLORY-3, which extended treatment to 48 weeks, showed continued weight loss trajectory without a clear plateau at the trial endpoint, suggesting mazdutide's glucagon component continues to drive energy expenditure even as GLP-1-mediated appetite suppression stabilizes. The GI tolerability profile was similar to survodutide - nausea and vomiting were the most common adverse events, manageable with dose titration.
Innovent is pursuing regulatory submissions in additional markets. The molecule's China approval provides real-world data that will inform global development timelines, though ethnic and dietary differences between Chinese and Western trial populations complicate direct extrapolation to FDA or EMA approval contexts.
Amycretin: Oral GLP-1 / Amylin - A Different Mechanistic Bet
Amycretin (NN9487) takes a fundamentally different approach from the GLP-1/glucagon co-agonist class. It is a unimolecular combination of GLP-1 receptor agonism and amylin receptor agonism. Amylin is a pancreatic peptide co-secreted with insulin that suppresses glucagon, delays gastric emptying, and signals satiety through the area postrema in the brainstem - independently of GLP-1 pathways. Combining the two targeting mechanisms in one molecule aims to produce additive satiety signaling without redundancy.
The headline feature is the oral formulation. Novo Nordisk has developed amycretin as an oral tablet using the same SNAC (sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]) absorption enhancer technology that makes oral semaglutide (Rybelsus) possible. Oral GLP-1 delivery is notoriously difficult due to peptide degradation in the GI tract and poor mucosal permeability - the SNAC technology protects the peptide in the gastric environment and transiently increases local mucosal pH to facilitate absorption.
Phase 1 and Phase 2 Data
Early Phase 1 data published by Novo Nordisk in 2024 showed oral amycretin produced 13.1% body weight loss at 12 weeks in a small cohort - a striking number for such a short duration and for an oral agent. The 12-week data generated significant attention because it suggested amycretin's dual mechanism might outperform oral semaglutide (which produces roughly 5% at 12 weeks on standard 14 mg dosing) despite using the same delivery route.
Phase 2 trials are underway as of 2026, evaluating multiple dose levels and longer treatment durations to establish the weight loss trajectory and safety profile at scale. Injectable amycretin formulations are also in parallel development, which will allow separation of the delivery mechanism from the pharmacological effect in clinical comparison.
The amylin component adds a mechanistic consideration not present in GLP-1/glucagon combinations: amylin receptor agonism is associated with nausea as a dose-limiting effect (the failed pramlintide injectable demonstrated this), so dose titration strategies for amycretin will likely be designed carefully to manage this additive GI burden.
Head-to-Head Context: How Do They Stack Up?
No direct head-to-head trials between these molecules and the established agents exist yet. The following comparison uses trial data across different populations, durations, and protocols - treat these numbers as directional context, not clinical equivalence claims.
- Semaglutide 2.4 mg (STEP-1, 68 weeks): 14.9% mean body weight loss, strong cardiovascular outcome data (SELECT trial), established GI tolerability profile, injectable.
- Tirzepatide 15 mg (SURMOUNT-1, 72 weeks): 20.9% mean body weight loss, GLP-1/GIP dual mechanism, SURMOUNT-MMO cardiovascular outcomes trial ongoing, injectable.
- Retatrutide 12 mg (Phase 2, 48 weeks): 24.2% mean body weight loss - triple GLP-1/GIP/glucagon agonism from Eli Lilly, currently in Phase 3 TRIUMPH program, injectable.
- Survodutide 6.0 mg (SYNCHRONIZE Phase 2, 46 weeks): ~18.7% mean body weight loss, strong MASH data, Phase 3 ongoing, injectable.
- Mazdutide 4.5 mg (GLORY-3, 48 weeks): approximately 14-16% body weight loss, approved in China, global trials ongoing, injectable.
- Amycretin oral (Phase 1, 12 weeks): 13.1% body weight loss at 12 weeks, oral formulation, Phase 2 ongoing - long-term trajectory unknown.
Retatrutide currently leads on weight loss magnitude among all agents in development, driven by its triple receptor engagement. Survodutide differentiates on MASH outcomes. Amycretin differentiates on oral delivery - which may matter more for population-scale adoption than for pure efficacy benchmarks.
Cardiovascular Outcomes: The New Battleground
The SELECT trial demonstrated semaglutide reduces major adverse cardiovascular events (MACE) by 20% in non-diabetic adults with obesity and established cardiovascular disease - independent of weight loss magnitude. This cardiovascular benefit has become a key differentiator in payer and prescriber decisions, beyond just weight loss numbers.
All three next-gen molecules are now running or planning cardiovascular outcomes trials. The glucagon receptor component in survodutide and mazdutide raises a question: glucagon is known to increase heart rate and has historically been associated with adverse cardiac effects at high doses. Phase 2 data from both molecules did not show clinically significant cardiac safety signals at therapeutic doses, but CVOT data will be needed to confirm cardiovascular neutrality or benefit before these molecules can compete with semaglutide on the full prescribing value proposition.
Expected Timelines and Market Implications
Realistic approval timelines based on current trial phase as of early 2026:
- Survodutide: Phase 3 data expected 2026-2027. If positive, NDA submission likely 2027-2028. US/EU approval possible 2028-2029 for obesity; MASH indication may come first given unmet need and accelerated pathway potential.
- Mazdutide: Already approved in China. Global filings depend on Innovent/Lilly strategy and whether additional RCT data in non-Asian populations is required by FDA/EMA. US availability before 2028 is uncertain.
- Amycretin: Phase 2 ongoing. Assuming positive Phase 2 results and rapid Phase 3 initiation, earliest realistic approval window is 2028-2029. The oral formulation could justify accelerated review if Phase 2 efficacy holds.
The competitive pressure these molecules create is already influencing the market. Novo Nordisk and Eli Lilly are not standing still - Novo is advancing the injectable cagrilintide+semaglutide combination (CagriSema) which showed 22.7% weight loss at 32 weeks in Phase 2, and Lilly's retatrutide is in Phase 3. The obesity drug landscape in 2028 will look dramatically different from 2024.
What This Means for Patients and Prescribers
The practical implication of a crowded next-gen pipeline is not simply that better drugs are coming. It is that the treatment paradigm for obesity is shifting from a one-size-fits-all approach toward precision matching of mechanism to patient phenotype. A patient with MASH and obesity may ultimately be better served by a GLP-1/glucagon agent than pure GLP-1 agonism. A patient with severe injection anxiety may be the primary candidate for oral amycretin. A patient who needs maximum weight loss with the strongest cardiovascular evidence will likely remain on a tirzepatide or semaglutide derivative.
The GI tolerability question cuts across all these molecules. Nausea, vomiting, and diarrhea remain the dominant class-wide adverse effects of GLP-1 based therapies, and adding glucagon or amylin receptor agonism appears to add GI burden rather than reduce it. Any agent that can match efficacy with better GI tolerability will have a significant clinical advantage.
Bottom Line
Survodutide, mazdutide, and amycretin each represent genuine mechanistic advances beyond first-generation GLP-1 agonism. Survodutide's glucagon co-agonism produces strong MASH efficacy data alongside competitive weight loss numbers. Mazdutide has already crossed the commercial threshold in China, providing real-world validation of the GLP-1/glucagon mechanism. Amycretin's oral GLP-1/amylin approach raises the ceiling on what oral obesity pharmacotherapy can achieve, with early data suggesting efficacy that exceeds oral semaglutide at comparable timepoints.
None of these molecules has completed Phase 3 trials outside of mazdutide's China approval. Weight loss benchmarks from Phase 2 trials consistently improve in Phase 3 protocols - and occasionally regress when trial designs tighten. The obesity pharmacotherapy landscape in 2026 is one of the most active in pharmaceutical history, and the agents covered here represent the most credible near-term challengers to the current standard of care.
All of this research involves pharmaceutical agents requiring prescriptions in regulated markets. None of the molecules covered here are available as research peptides, and none should be self-administered outside of a clinical trial or licensed medical context.